H.C. Wainwright resumed coverage on MetaVia with a new price target
$MTVA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $12.00 | Buy | H.C. Wainwright |
CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001 ("common stock"), effective at 5:00 p.m. Eastern Time on December 4, 2025. Beginning on December 5, 2025, the common stock will trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis. At the Company's annual meeting of stockholders on June 30, 2025, the stockholders approved a proposal
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of positive new data from its Phase 2a clinical trial evaluating vanoglipel (DA-1241), a potent and selective G protein-coupled receptor 119 (GPR119) agonist, as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH). The data highlight vanoglipel's differentiated dual activity across both hepatic a
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected by Year-End 2025 $14.3 Million in Cash at End of Third Quarter is Expected to Fund the Company Into 2026 CAMBRIDGE, Mass., Nov. 6, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate strategic update.
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)